ALN
Neovacs
Stock
Stock
ISIN: FR001400TG47
Ticker: ALNEV
FR001400TG47
ALNEV
Price
Price
CHART BY
Frequently asked questions
What is Neovacs's market capitalization?
The market capitalization of Neovacs is 953.25K. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Neovacs?
Neovacs's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$33,203.52. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Neovacs's stock?
Currently, 1 analysts cover Neovacs's stock, with a consensus target price of 3,200,000,000,000,000.00. Analyst ratings provide insights into the stock's expected performance.
What is Neovacs's revenue over the trailing twelve months?
Over the trailing twelve months, Neovacs reported a revenue of 291.31K.
What is the EBITDA for Neovacs?
Neovacs's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -6.57M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Neovacs?
Neovacs has a free cash flow of -3.68M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Financials
- Market Cap
- 953.25K
- EPS (TTM)
- -$33,203.52
- Revenue (TTM)
- 291.31K
- EBITDA (TTM)
- -6.57M
- Free Cashflow (TTM)
- -3.68M
Pricing
- 1D span
- $0.001967$0.002209
- 52W span
- $0.0001042$3.331
Analyst Ratings
The price target is 3,200,000,000,000,000.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The firm is developing a product portfolio using its Kinoid technology through self-antigens, which cause autoimmune or inflammatory diseases. Its product portfolio includes IFNa kinoid, IL-4/13 kinoid, and IgE kinoid. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- FR001400TG47
- Primary Ticker
- ALNEV
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet